CANDONI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 14.425
NA - Nord America 12.088
EU - Europa 6.480
SA - Sud America 1.602
AF - Africa 211
OC - Oceania 44
Continente sconosciuto - Info sul continente non disponibili 8
Totale 34.858
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.792
CN - Cina 5.146
SG - Singapore 3.969
IT - Italia 1.896
HK - Hong Kong 1.759
GB - Regno Unito 1.360
BR - Brasile 1.266
KR - Corea 970
VN - Vietnam 940
FI - Finlandia 897
BD - Bangladesh 455
RU - Federazione Russa 386
DE - Germania 385
SE - Svezia 344
FR - Francia 329
IN - India 246
ID - Indonesia 240
NL - Olanda 203
LT - Lituania 129
JP - Giappone 127
AR - Argentina 125
CA - Canada 119
MX - Messico 113
TR - Turchia 109
UA - Ucraina 109
IQ - Iraq 100
IE - Irlanda 69
AT - Austria 64
ZA - Sudafrica 53
AE - Emirati Arabi Uniti 52
EC - Ecuador 51
BG - Bulgaria 46
PK - Pakistan 46
AU - Australia 42
ES - Italia 41
CZ - Repubblica Ceca 39
CO - Colombia 38
PL - Polonia 36
SA - Arabia Saudita 29
CL - Cile 28
UZ - Uzbekistan 28
VE - Venezuela 28
KE - Kenya 26
TN - Tunisia 26
EG - Egitto 25
MA - Marocco 25
PY - Paraguay 25
TW - Taiwan 23
MY - Malesia 18
PH - Filippine 18
TH - Thailandia 18
DZ - Algeria 17
NP - Nepal 17
UY - Uruguay 16
CH - Svizzera 15
JO - Giordania 14
PE - Perù 14
PT - Portogallo 14
RO - Romania 14
BE - Belgio 13
IL - Israele 13
OM - Oman 13
HN - Honduras 12
BY - Bielorussia 11
BO - Bolivia 10
DO - Repubblica Dominicana 10
GR - Grecia 10
HU - Ungheria 10
DK - Danimarca 9
AZ - Azerbaigian 8
JM - Giamaica 8
KZ - Kazakistan 8
AL - Albania 7
GT - Guatemala 7
HR - Croazia 7
PS - Palestinian Territory 7
SY - Repubblica araba siriana 7
AO - Angola 6
CR - Costa Rica 6
EU - Europa 6
KG - Kirghizistan 6
QA - Qatar 6
SK - Slovacchia (Repubblica Slovacca) 6
TT - Trinidad e Tobago 6
IR - Iran 5
RS - Serbia 5
BA - Bosnia-Erzegovina 4
ET - Etiopia 4
LB - Libano 4
LV - Lettonia 4
MD - Moldavia 4
MN - Mongolia 4
NI - Nicaragua 4
NO - Norvegia 4
UG - Uganda 4
BB - Barbados 3
BH - Bahrain 3
BN - Brunei Darussalam 3
CI - Costa d'Avorio 3
EE - Estonia 3
Totale 34.802
Salva come PNG Salva come JPEG
Città #
Hefei 3.358
Singapore 2.397
Santa Clara 1.740
Hong Kong 1.667
Ashburn 1.604
San Jose 1.072
Seoul 963
Helsinki 816
London 689
Council Bluffs 582
Fairfield 511
The Dalles 428
Southend 381
Ho Chi Minh City 330
Los Angeles 320
Beijing 315
Houston 273
Woodbridge 260
Milan 256
Chicago 228
Seattle 224
Lauterbourg 219
New York 214
Hanoi 203
Chandler 195
Kent 194
Nyköping 191
Jakarta 180
Wilmington 174
Cambridge 159
Ann Arbor 158
Buffalo 157
Dallas 149
Rome 148
Boardman 133
Jacksonville 131
São Paulo 129
Dearborn 114
Moscow 113
Munich 107
Salt Lake City 93
Shanghai 91
Amsterdam 90
Redondo Beach 80
Columbus 73
Dublin 68
Frankfurt am Main 68
Modena 68
San Diego 68
Bologna 61
Nuremberg 61
Tokyo 61
Reggio Emilia 56
Mexico City 55
Elk Grove Village 54
Da Nang 51
Delhi 50
Tampa 49
Hillsboro 42
Phoenix 42
Washington 42
Atlanta 41
Guangzhou 41
Brooklyn 40
Princeton 40
Sofia 40
Rio de Janeiro 39
Baghdad 38
Belo Horizonte 36
Miano 36
Izmir 35
Boston 32
Miami 32
Kilburn 30
Lappeenranta 30
Orem 30
Eugene 29
Florence 29
Toronto 29
Turin 28
Mumbai 27
Shenzhen 27
Montreal 26
Naples 26
Vienna 26
Brasília 25
Curitiba 25
Haiphong 25
Johannesburg 25
Warsaw 25
Biên Hòa 24
Sterling 24
Tashkent 24
Turku 24
Guarulhos 23
Melbourne 23
Quito 23
Brno 22
Porto Alegre 22
Bari 21
Totale 23.947
Salva come PNG Salva come JPEG
Nome #
Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients 427
Mucorales-specific T cells in patients with hematologic malignancies 363
A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients 353
invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. 315
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 312
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 308
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) 297
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 288
Identification and characterization of Aspergillus-specific immune responses to diagnose invasive aspergillosis in high risk patients: a multicenter study 265
Mucorles-specific T cells emerge in the course of invasive mucormucosis and may be used as a surrogate diagnostic marker in high-risk patients 263
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 253
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers 253
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 253
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study 251
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 238
Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: Feasibility and utility (SEIFEM-2008B study) 234
PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study. 223
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. 223
Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia 222
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) 217
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 216
Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation 215
Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results. 214
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. 214
Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management 210
Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies 207
Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use 206
SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy 204
The Role of Wilms’ Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia 203
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 201
Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. 199
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 199
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 196
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 186
PEG Interferon a-2b (PEG-Intron) in Essential Thrombocythemia: Phase II Study for Determination of the Minimum Effective, Safe and Tolerated Dose. Preliminary Data. 186
Bone marrow biopsy and aspirate evaluation in 90 patients with Essential Thrombocythemia treated with PEG interferon alpha-2b. Preliminary results 186
Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study 185
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 185
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients 184
European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group 184
10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG 183
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study 180
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study 180
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial 177
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature 177
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience 172
Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program 171
Pneumocystis jirovecii pneumonia at chest High-resolution Computed Tomography (HRCT)in non-HIV immunocompromised patients: Spectrum of findings and mimickers 169
Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience 164
Advanced mast cell disease: An Italian Hematological Multicenter experience 163
Acute myeloid leukemia in patients previously diagnosed with breast cancer: Experience of the GIMEMA group 163
COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit 163
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry 162
Intravascular lymphoma: Clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant' 161
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia 159
Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: An Italian multicentre prospective survey 157
PEG Interferon alpha2b (PEG Intron) in Essential Thrombocytemia: Phase II Study for Determination of the Minimun Effective, Safe and Tolerated Dose. Preliminary Data. 157
Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial 155
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma 154
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 154
Antibody Binding Capacity for Evaluation of MDR-Related Proteins in Acute Promyclocytic Leukemia: Onset Versus Relapse Expression 151
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia 150
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 149
Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax 147
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 146
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia 144
FLAI induction regimen in elderly patients with acute myeloid leukemia 143
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 143
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy 143
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE) 141
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial 141
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 138
Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients 138
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia 137
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 137
Systemic antifungal treatment after posaconazole prophylaxis: Results from the SEIFEM 2010-C survey 136
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial 136
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 135
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 133
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO) 133
Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination 132
Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study 131
Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series 129
A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia 129
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia 128
Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia 127
Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study 127
Revision of antifungal strategies definitions for invasive fungal infections (proven/probable/possible) in 461 patients with haematological malignancies (REDEFI-SEIFEM) 126
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax 125
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia 125
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 124
Fungaemia in haematological malignancies: SEIFEM-2015 survey 124
Real-Time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: Results from a prospective, monocentric, interventional study 123
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 122
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience 122
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes 122
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia 121
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 120
Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey 120
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 119
Totale 18.176
Salva come PNG Salva come JPEG
Categoria #
all - tutte 183.272
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 183.272
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202156 0 0 0 0 0 0 0 0 0 0 0 56
2021/2022729 38 101 59 44 30 57 34 42 87 52 90 95
2022/20231.245 79 47 43 53 88 87 319 130 200 28 72 99
2023/20242.253 58 67 144 201 370 187 325 230 54 65 223 329
2024/20259.093 215 113 95 617 1.537 1.057 386 344 1.011 881 1.524 1.313
2025/202619.174 1.788 1.482 2.443 1.986 1.233 1.262 2.701 850 1.534 1.652 1.633 610
Totale 35.236